To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

April 15, 2019

Today's Rundown

Featured Story

Hatteras raises $94M to invest in early-stage biotechs

Hatteras Venture Partners has raised $94 million for its sixth venture fund. The first close of the targeted $200 million fund tees Hatteras up to make a fresh batch of seed and early-stage biotech investments. 

Top Stories

Early Alzheimer's biotech, late-stage heart drug company gun for $86M IPOs

Two very different biotechs—one focused on pushing through an early Alzheimer’s disease drug and the other a phase 3 heart rate condition company—are looking for the very same IPO price.

Applied Therapeutics eyes $86M IPO to advance metabolic disease programs

The IPO will bankroll a trio of assets through the clinic, including two for complications of diabetes and one for galactosemia, a rare genetic disorder.

[Sponsored] Mitotech: a Dry Eye treatment aimed at mitochondria

Mitotech – a biotech specializing in targeting mitochondria – is moving into late stage of clinical development in Dry Eye Disease.

EIP bags cash to trial ex-Vertex drug in dementia, Huntington's

EIP Pharma has raised $11.2 million to expand its clinical trial activities beyond Alzheimer's disease. The cash will fund midphase trials of an ex-Vertex drug in dementia and Huntington's disease.

Fibrocell, Castle Creek ink rare disease gene therapy pacts worth up to $135M

Castle Creek will assume manufacturing and development costs for Fibrocell's gene therapy for recessive dystrophic epidermolysis bullosa until the duo files for FDA approval.

Bringing CAR-T cancer treatments to solid tumors with help from alpacas

Scientists at Boston Children's Hospital and MIT built CAR-T cells that are inspired by alpaca antibodies and can target protective proteins around solid tumors. They plan to test the approach in pancreatic and bile duct cancers.

Catalent pulls off $1.2B deal for gene therapy CDMO Paragon Bioservices

In the second major buyout of a gene therapy manufacturer in the last three weeks, Catalent snapped up Paragon Bioservices in a $1.2 billion deal.

Resources

[Whitepaper] Personalized Test for Treatment Prediction in Depression

Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy.

[Whitepaper] Observed Impact of Medication Price Transparency on Patients and Practices

Prescription price transparency technology is here – but is it making a difference? Find out HERE.

[Whitepaper] Redefining Your Value to Win Empowered Patients: Six Steps to Success

Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver?

[Whitepaper] Key Life Sciences Trends, 2019 and Beyond

The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries.

[Whitepaper] The New World of Allosteric Modulation: Another Shot on Goal

Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more.

[Whitepaper] Advanced HDX-MS and Native-MS for Improved Biologic Candidate Selection and Development

Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate.

[Whitepaper] Workbench for Biomarker and Translational Research

Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma.

[Whitepaper] Meet Our Uncle: 12 Protein Stability Applications on One Platform

Download this whitepaper to learn more!

[Whitepaper] Flow Chemistry For Modern API Development & Manufacturing

Is Flow Chemistry right for your API Development?

[Whitepaper] Systolic Heart Failure: Real-World Study Using Electronic Health Records

Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care.

[Article] Are you ready for 2008 Microsoft SQL and Windows Servers end of life?

Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage.

[Whitepaper] Better Market Intelligence With Smart Search

From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve.

[Whitepaper] Accelerating Clinical Trials through Access to Real-World Patient Data

Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs.

[Case Study] TriCore Reference Laboratories Transforms to Clinical Lab 2.0 Model

Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events